COTTRELL SANDRA 4
4 · NPS PHARMACEUTICALS INC · Filed Dec 21, 2012
Insider Transaction Report
Form 4
SANDRA COTTRELL
VP, Reg. Affairs & Drug Safety
Transactions
- Award
Stock Options
2012-12-21+64,000→ 64,000 totalExercise: $3.34Exp: 2020-02-19→ Common Stock (64,000 underlying)
Footnotes (1)
- [F1]On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. On December 21, 2012, the performance criteria for 64,000 of these options was satisfied when the FDA unanimously voted to approve the NDA for GATTEX for the treatment of SBS. These options will vest and become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.